OBJECTIVES: Discordance between the Gleason score (GS) on needle biopsy (NB) and the GS of the radical prostatectomy (RP) specimen is a common finding. The objective of this study was to evaluate the prognostic significance of these discrepancies with respect to outcomes following RP. METHODS: In the study, 6625 men treated by RP were categorized as having NB=RP (68.8%), NB<RP (25.0%) or NB>RP (6.2%) GS, and stratified for analyses into RP GS groups. The Kaplan-Meier method was used to analyze differences in biochemical recurrence-free survival (BRFS), and multivariate Cox analyses were performed to estimate the independent relative risk of progression associated with GS discrepancies. RESULTS: Across multiple RP GS strata (3+4, 7, 8, 8-10), patients with a lower NB GS experienced significantly better BRFS than patients with equal NB and RP GS (all p<0.05). NB<RP GS was independently associated with better (pooled HR, 0.76, p=0.001) BRFS, within and across RP GS strata. Similarly, patients with NB>RP GS had poorer BRFS than patients with NB=RP GS across multiple RP GS strata (< or =3+3, 3+4, 7; all p<0.05). NB>RP GS was independently associated with worse (pooled HR, 1.91, p<0.001) BRFS probabilities, within and across RP GS strata. CONCLUSIONS: Our data suggest that the GS of the NB adds additional prognostic value to the RP GS in a consistent manner that may be applicable to strategies of risk stratification and patient counseling after surgery.
OBJECTIVES: Discordance between the Gleason score (GS) on needle biopsy (NB) and the GS of the radical prostatectomy (RP) specimen is a common finding. The objective of this study was to evaluate the prognostic significance of these discrepancies with respect to outcomes following RP. METHODS: In the study, 6625 men treated by RP were categorized as having NB=RP (68.8%), NB<RP (25.0%) or NB>RP (6.2%) GS, and stratified for analyses into RP GS groups. The Kaplan-Meier method was used to analyze differences in biochemical recurrence-free survival (BRFS), and multivariate Cox analyses were performed to estimate the independent relative risk of progression associated with GS discrepancies. RESULTS: Across multiple RP GS strata (3+4, 7, 8, 8-10), patients with a lower NB GS experienced significantly better BRFS than patients with equal NB and RP GS (all p<0.05). NB<RP GS was independently associated with better (pooled HR, 0.76, p=0.001) BRFS, within and across RP GS strata. Similarly, patients with NB>RP GS had poorer BRFS than patients with NB=RP GS across multiple RP GS strata (< or =3+3, 3+4, 7; all p<0.05). NB>RP GS was independently associated with worse (pooled HR, 1.91, p<0.001) BRFS probabilities, within and across RP GS strata. CONCLUSIONS: Our data suggest that the GS of the NB adds additional prognostic value to the RP GS in a consistent manner that may be applicable to strategies of risk stratification and patient counseling after surgery.
Authors: Attila Majoros; Attila Marcell Szász; Péter Nyirády; Eszter Székely; Péter Riesz; Attila Szendrői; Attila Keszthelyi; Janina Kulka; Imre Romics Journal: Int Urol Nephrol Date: 2013-08-30 Impact factor: 2.370
Authors: Michelangelo Fiorentino; Gregory Judson; Kathryn Penney; Richard Flavin; Jennifer Stark; Christopher Fiore; Katja Fall; Neil Martin; Jing Ma; Jennifer Sinnott; Edward Giovannucci; Meir Stampfer; Howard D Sesso; Philip W Kantoff; Stephen Finn; Massimo Loda; Lorelei Mucci Journal: Cancer Res Date: 2010-04-13 Impact factor: 12.701
Authors: A Pichon; Y Neuzillet; H Botto; J-P Raynaud; C Radulescu; V Molinié; J-M Herve; T Lebret Journal: Prostate Cancer Prostatic Dis Date: 2015-10-06 Impact factor: 5.554
Authors: Qiang Fu; Judd W Moul; Lionel L Bañez; Leon Sun; Vladimir Mouraviev; Dongha Xie; Thomas J Polascik Journal: Med Oncol Date: 2012-06-12 Impact factor: 3.064
Authors: Carmen A Perez; Heidi Chen; Yu Shyr; Regina Courtney; Wei Zheng; Qiuyin Cai; Misun Hwang; Jerry Jaboin; Stephen Schleicher; Luigi Moretti; Marcia Wills; Joseph A Smith; Bo Lu Journal: J Urol Date: 2010-03-19 Impact factor: 7.450
Authors: Timothy N Clinton; Aditya Bagrodia; Yair Lotan; Vitaly Margulis; Ganesh V Raj; Solomon L Woldu Journal: Expert Rev Precis Med Drug Dev Date: 2017-09-05